Next Article in Journal
High-Mobility Group Box 1 Mediates Fibroblast Activity via RAGE-MAPK and NF-κB Signaling in Keloid Scar Formation
Next Article in Special Issue
Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets
Previous Article in Journal
Thiopurine Drugs Repositioned as Tyrosinase Inhibitors
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(1), 74;

Targeted α Therapies for the Treatment of Bone Metastases

UOC Oncologia, ULSS 1 Dolomiti, Belluno Medical Hospital “San Martino”, Viale Europa 22, 32100 Belluno, Italy
Bayer Spa, Viale Certosa 210, 201156 Milan, Italy
Author to whom correspondence should be addressed.
Received: 14 November 2017 / Revised: 27 November 2017 / Accepted: 6 December 2017 / Published: 28 December 2017
(This article belongs to the Special Issue Bone Metastasis: Pathophysiology and Molecular Mechanisms)
Full-Text   |   PDF [620 KB, uploaded 28 December 2017]   |  


The skeleton is the target tissue for many types of tumors, and, recently, the survival of patients with prostate cancer metastasis has been increased using α-emitting drugs known as targeted α therapies. The use of α-radiopharmaceuticals in medicine was hypothesized at the beginning of the nineteenth century after the observation that α-radionuclides were associated with high cell-killing energy and low tissue penetration in healthy tissues. In the prostate cancer (PC) scenario, current research suggests that this class of radiopharmaceuticals has limited toxicity, and that the mechanism of action does not overlap with pre-existing drugs, allowing us to extend therapeutic armaments and address medical oncology towards personalized and precision medicine. Ongoing studies may extend these benefits also to bone metastases deriving from other neoplasms. The aim of this review is to summarize the current research on targeted α therapies and try to identify the right patient to be treated in the right time in order to integrate in these medications in the every-day clinical practice. View Full-Text
Keywords: radium 223; bone metastases; breast cancer; prostate cancer; tumour cell dormancy radium 223; bone metastases; breast cancer; prostate cancer; tumour cell dormancy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zustovich, F.; Barsanti, R. Targeted α Therapies for the Treatment of Bone Metastases. Int. J. Mol. Sci. 2018, 19, 74.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top